The Aptus Therapeutics-backed neurodegenerative disorder drug developer has filed for an $80.5m initial public offering on Nasdaq after raising roughly $30m in VC funding.
Alzheon, a US-based developer of treatments for neurodegenerative disorders, has filed to raise up to $80.5m in an initial public offering that will enable pharmaceutical company Aptus Therapeutics to exit.
Founded in 2013, Alzheon is working on developing small molecules that will combat neurodegenerative disorders such as Alzheimer’s disease by inhibiting protein misfolding, a process where proteins do not fold correctly, leading to them becoming damaged or toxic.
The IPO proceeds will go to advancing Alzheon’s lead drug candidate,…
